重组人干扰素α-1b联合匹多莫德对反复呼吸道感染患者免疫功能的影响

Effect of recombinant human interferon α-1b combined with Pidotimod on the immune function in the patients with recurrent respiratory tract infection

目的研究重组人干扰素α-1b联合匹多莫德对反复呼吸道感染(RRTI)患者免疫功能的影响。方法选取96例反复呼吸道感染患者作为RRTI组,随机分为治疗组与对照组2个亚组;另选50例健康人群作为正常对照组。治疗组采用重组人干扰素α-1b联合匹多莫德治疗,对照组采用常规治疗。观察并比较治疗前后T细胞亚群和免疫球蛋白水平的变化。结果治疗前RRTI组CD3+T细胞比例、CD4+T细胞比例、CD4+/CD8+、Ig G、Ig A、Ig M水平显著低于正常对照组,CD8+T细胞比例显著高于正常对照组(P均<0.05);治疗后,治疗组CD8+T细胞比例显著低于治疗前,CD3+T细胞比例、CD4+T细胞比例、CD4+/CD8+、Ig G、Ig A、Ig M水平显著高于治疗前(P均<0.05);治疗组CD8+T细胞比例显著低于对照组,CD3+T细胞比例、CD4+T细胞比例、CD4+/CD8+、Ig G、Ig A、Ig M水平显著高于对照组,差异均有统计学意义(P均<0.05)。结论重组人干扰素α-1b联合匹多莫德治疗RRTI患者能够增强细胞免疫和体液免疫功能,保护患者的呼吸道健康,可以应用于临床推广。

Objective It is to observe the effect of recombinant human interferon α - 1 b combined with Pidotimod on the immune function in the patients with recurrent respiratory tract infection （RRTI）. Methods 96 cases of patients with RRIT were selected as RRTI group, and were divided randomly into two sub groups： treatment group and control group; 50 cases of healthy people were selected as normal control group. The treatment group was treated with recombinant human interferonα - 1b combined with Pidotimod, the control group was treated with normal therapy. The changes of levels of subgroup of T cells and immunoglobulin？ before and after treatment were observed in both groups. Results Before treatment, the proportion of CD3 ＋ T cells and CD4 ＋ T cells, CD3 ＋/CD4 ＋ , the levels of IgG, IgA, IgM in RRTI group were significantly lower while the proportion of CD8 ＋ T cells was higher than that in the normal control group （ P 〈 0. 05 ）. After treatment, the proportion of CD8＋ T cells was lower, while the proportion of CD3＋ T cells and CD4 ＋ T cells, CD3 ＋/CD4＋ , the levels of IgG, IgA, IgM were higher than that before treatment in treatment group （all P 〈 0.05 ） ; the proportion of CD8 ＋ T cells was lower, while the proportion of CD3 ＋ T cells and CD4 ＋ T cells, CD3 ＋/CD4 ＋ , the levels of IgG, IgA, IgM were higher in treatment group than that in control group, the differences were all significant （ all P 〈 0.05 ）. Conclusion Recombinant human interferonα - 1 b combined with Pidotimod can improve celluler immunity andhumoral immunity function, protect respiratory tract in the patients with RRTI, which should be widely applicated in clinic.